Legato Capital Management LLC Invests $305,000 in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Legato Capital Management LLC bought a new stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) in the 4th quarter, Holdings Channel.com reports. The fund bought 12,960 shares of the company’s stock, valued at approximately $305,000.

Other large investors have also recently added to or reduced their stakes in the company. Quantbot Technologies LP purchased a new stake in Dyne Therapeutics in the 3rd quarter valued at about $34,000. Point72 DIFC Ltd acquired a new stake in shares of Dyne Therapeutics in the third quarter worth approximately $36,000. US Bancorp DE grew its holdings in Dyne Therapeutics by 776.9% in the third quarter. US Bancorp DE now owns 1,368 shares of the company’s stock valued at $49,000 after purchasing an additional 1,212 shares during the period. Values First Advisors Inc. acquired a new position in Dyne Therapeutics during the third quarter worth approximately $62,000. Finally, KBC Group NV raised its stake in Dyne Therapeutics by 53.4% during the third quarter. KBC Group NV now owns 2,157 shares of the company’s stock worth $77,000 after purchasing an additional 751 shares during the period. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have recently issued reports on DYN. Baird R W raised shares of Dyne Therapeutics to a “strong-buy” rating in a research note on Thursday, December 12th. HC Wainwright reissued a “buy” rating and set a $55.00 price target on shares of Dyne Therapeutics in a research report on Friday, January 10th. Robert W. Baird assumed coverage on Dyne Therapeutics in a report on Friday, December 13th. They issued an “outperform” rating and a $46.00 price objective on the stock. Guggenheim reiterated a “buy” rating on shares of Dyne Therapeutics in a report on Friday, January 24th. Finally, JPMorgan Chase & Co. downgraded shares of Dyne Therapeutics from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $43.00 to $35.00 in a research report on Thursday, October 24th. One analyst has rated the stock with a sell rating, one has issued a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Dyne Therapeutics has an average rating of “Moderate Buy” and an average price target of $49.91.

Dyne Therapeutics Trading Down 1.0 %

DYN opened at $13.91 on Friday. Dyne Therapeutics, Inc. has a twelve month low of $13.07 and a twelve month high of $47.45. The firm has a market cap of $1.42 billion, a price-to-earnings ratio of -3.91 and a beta of 1.11. The company has a fifty day simple moving average of $19.45 and a 200 day simple moving average of $29.73.

Dyne Therapeutics (NASDAQ:DYN) last announced its earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). On average, analysts forecast that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Insider Buying and Selling at Dyne Therapeutics

In other Dyne Therapeutics news, SVP Richard William Scalzo sold 1,455 shares of the firm’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total transaction of $40,914.60. Following the completion of the transaction, the senior vice president now directly owns 127,078 shares of the company’s stock, valued at $3,573,433.36. This trade represents a 1.13 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Oxana Beskrovnaya sold 2,334 shares of the company’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total transaction of $65,632.08. Following the completion of the sale, the insider now owns 201,685 shares in the company, valued at approximately $5,671,382.20. This trade represents a 1.14 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 20,289 shares of company stock worth $580,592 in the last 90 days. 20.77% of the stock is owned by corporate insiders.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.